Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Moderna Finally Ready To Make A ‘Big Commitment’ On Not-For-Profit COVID-19 Vaccines?

Last Company To Pledge

Executive Summary

Some countries want an IP waiver to boost access to vaccines, but industry leaders say this will do nothing to increase output.

You may also be interested in...



Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease

Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.

Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results

Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.

Curis And Autolus Rise On EHA Abstract Data

Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel